GM Advisory Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $915K | Buy |
32,594
+1,626
| +5% | +$43.3K | 0.04% | 177 |
|
|
2025
Q4 | $771K | Buy |
30,968
+2,975
| +11% | +$75K | 0.03% | 181 |
|
|
2025
Q3 | $713K | Sell |
27,993
-2,891
| -9% | -$71.4K | 0.03% | 169 |
|
|
2025
Q2 | $749K | Buy |
30,884
+450
| +1% | +$10.5K | 0.04% | 170 |
|
|
2025
Q1 | $771K | Buy |
30,434
+1,629
| +6% | +$42.6K | 0.04% | 146 |
|
|
2024
Q4 | $764K | Sell |
28,805
-66
| -0.2% | -$1.79K | 0.04% | 139 |
|
|
2024
Q3 | $836K | Sell |
28,871
-1,861
| -6% | -$54.3K | 0.05% | 127 |
|
|
2024
Q2 | $860K | Sell |
30,732
-5,000
| -14% | -$138K | 0.06% | 123 |
|
|
2024
Q1 | $992K | Buy |
35,732
+5,402
| +18% | +$150K | 0.07% | 111 |
|
|
2023
Q4 | $873K | Buy |
30,330
+11,398
| +60% | +$345K | 0.07% | 102 |
|
|
2023
Q3 | $628K | Sell |
18,932
-2,061
| -10% | -$72.9K | 0.05% | 108 |
|
|
2023
Q2 | $770K | Buy |
20,993
+142
| +0.7% | +$5.53K | 0.06% | 95 |
|
|
2023
Q1 | $851K | Buy |
20,851
+681
| +3% | +$29.4K | 0.08% | 85 |
|
|
2022
Q4 | $1.03M | Sell |
20,170
-125
| -0.6% | -$5.99K | 0.11% | 70 |
|
|
2022
Q3 | $888K | Buy |
20,295
+704
| +4% | +$34.2K | 0.11% | 70 |
|
|
2022
Q2 | $1.03M | Buy |
19,591
+1,173
| +6% | +$59.8K | 0.16% | 65 |
|
|
2022
Q1 | $953K | Buy |
18,418
+2,683
| +17% | +$139K | 0.11% | 91 |
|
|
2021
Q4 | $929K | Buy |
15,735
+500
| +3% | +$24.8K | 0.08% | 98 |
|
|
2021
Q3 | $655K | Buy |
15,235
+3
| +0% | +$133 | 0.07% | 112 |
|
|
2021
Q2 | $596K | Buy |
15,232
+9
| +0.1% | +$350 | 0.06% | 118 |
|
|
2021
Q1 | $552K | Buy |
15,223
+2,733
| +22% | +$97K | 0.07% | 113 |
|
|
2020
Q4 | $460K | Buy |
12,490
+1,817
| +17% | +$66.6K | 0.06% | 109 |
|
|
2020
Q3 | $372K | Buy |
10,673
+2,809
| +36% | +$98.5K | 0.06% | 112 |
|
|
2020
Q2 | $244K | Sell |
7,864
-66
| -0.8% | -$2.24K | 0.05% | 152 |
|
|
2020
Q1 | $246K | Buy |
+7,930
| New | +$270K | 0.07% | 104 |
|
|
2019
Q4 | – | Sell |
-7,401
| Closed | -$252K | – | 116 |
|
|
2019
Q3 | $252K | Buy |
7,401
+1,583
| +27% | +$57.6K | 0.08% | 91 |
|
|
2019
Q2 | $239K | Hold |
5,818
| – | – | 0.08% | 94 |
|
|
2019
Q1 | $234K | Sell |
5,818
-1,581
| -21% | -$63.3K | 0.08% | 94 |
|
|
2018
Q4 | $306K | Sell |
7,399
-1,581
| -18% | -$65.6K | 0.11% | 75 |
|
|
2018
Q3 | $375K | Buy |
8,980
+262
| +3% | +$10.1K | 0.12% | 75 |
|
|
2018
Q2 | $300K | Sell |
8,718
-2,732
| -24% | -$93.4K | 0.09% | 85 |
|
|
2018
Q1 | $386K | Sell |
11,450
-1,702
| -13% | -$58.5K | 0.12% | 75 |
|
|
2017
Q4 | $452K | Hold |
13,152
| – | – | 0.12% | 70 |
|
|
2017
Q3 | $445K | Sell |
13,152
-2,793
| -18% | -$89.8K | 0.14% | 67 |
|
|
2017
Q2 | $508K | Sell |
15,945
-1,242
| -7% | -$39.2K | 0.16% | 62 |
|
|
2017
Q1 | $558K | Buy |
17,187
+2,164
| +14% | +$68.2K | 0.19% | 57 |
|
|
2016
Q4 | $463K | Buy |
+15,023
| New | +$459K | 0.16% | 68 |
|
|
2014
Q4 | – | Sell |
-10,192
| Closed | -$286K | – | 83 |
|
|
2014
Q3 | $286K | Buy |
10,192
+2,153
| +27% | +$60.4K | 0.21% | 49 |
|
|
2014
Q2 | $226K | Buy |
8,039
+158
| +2% | +$4.5K | 0.2% | 63 |
|
|
2014
Q1 | $234K | Buy |
7,881
+380
| +5% | +$11.3K | 0.18% | 66 |
|
|
2013
Q4 | $218K | Buy |
+7,501
| New | +$218K | 0.22% | 58 |
|
Other funds holding PFE
VCM
VPM
GM Advisory Group's PFE Position: Q1 2026 in Review
GM Advisory Group increased its Pfizer (PFE) stake by 5.3% in Q1 2026, buying an estimated $43.3K and bringing the position to 32,594 shares worth $915K. The position accounts for 0.04% of the portfolio, ranked #177.
GM Advisory Group first reported a position in PFE in Q4 2013 and has held it in 41 quarters since. The position peaked at $1.03M in Q4 2022. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- GM Advisory Group held 32,594 shares of Pfizer worth $915K as of Q1 2026.
- GM Advisory Group bought 1,626 Pfizer shares in Q1 2026, an estimated $43.3K.
- Pfizer made up 0.04% of GM Advisory Group's portfolio in Q1 2026, its #177 holding.
- GM Advisory Group first reported a position in Pfizer in Q4 2013 and has held it in 41 quarters since.
- GM Advisory Group's Pfizer position peaked at $1.03M in Q4 2022.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on GM Advisory Group's 13F filing for Q1 2026, filed 28 Apr 2026.